StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
ONMD$0.78+1.09%
Fair $0.78+0.0%

ONMD

OneMedNet Corporation

Healthcare / Health Information ServicesNasdaqCM

$0.78

+0.01 (+1.09%)

Fairly Valued+0.0%Fair Value $0.78Fund rank 30/100 · Data gapFallback financials|
SA 33/D
F-Score: 3/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-7.0M · quality 69.3/100

Data gap 30/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 34/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

33/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 5Warnings: 0unknown: 5
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · ONMDLocal privado en este navegador · OneMedNet Corporation
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$42M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

94.5%

↑

Gross Margin

-37.0%

↓

Debt/Equity

-0.19

↓
52-Week Range$1
$0$4

TradingView lightweight chart

ONMD price, volumen y niveles de valoración

Último $0.779Periodo -92.1%
Fair value: $0.779

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2025 · 4 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

-553.1%

FCF / Net income

2.68x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.4M · net income $-2.8M · FCF $-7.5M

2021-FY → 2025-FY

Gross margin

-37.0%— pts

Operating margin

-711.3%— pts

Net margin

-206.1%— pts

FCF margin

-553.1%— pts
MetricTTM
2025
2024
2023
2022
2021
Income Statement
Revenue$1.4M$1.4M$643000.00$1.0M$1.2M—
Net Income$-2.8M$-2.8M$-10.1M$-33.8M$-30.5M$5.1M
EBITDA$-2.7M$-2.7M$-9.9M$-33.7M$-30.4M—
EPS——-0.36-4.65-7.550.44
Gross Margin-37.0%-37.0%-43.7%-12.6%-31.2%—
Operating Margin-711.3%-711.3%-1493.8%-671.2%-1369.3%—
Net Margin-206.1%-206.1%-1575.3%-3308.5%-2641.0%—
Balance Sheet
Debt/Equity-0.19-0.19-0.55-0.38-1.00—
Current Ratio0.270.27————
Cash Flow
Free Cash Flow$-7.5M$-7.5M$-7.0M$-4.8M$-4.8M—
Returns
ROE94.5%94.5%63.5%251.3%115.5%-72.8%
Growth & Yield
Revenue Growth111.4%111.4%-37.0%-11.4%——
EPS Growth——92.3%38.4%——

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +94.8%

Total return

+94.8%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.36 → n/d

Residual

+94.8%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+94.8%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.